Sarepta Therapeutics logo

Sarepta TherapeuticsNASDAQ: SRPT

Profile

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

04 June 1997

Next earnings report:

28 February 2025

Last dividends:

N/A

Next dividends:

N/A
$10.94 B
-29%vs. 3y high
93%vs. sector
-81%vs. 3y high
86%vs. sector
-75%vs. 3y high
91%vs. sector
-56%vs. 3y high
68%vs. sector

Price

after hours | 41 min ago
$114.50+$3.95(+3.57%)

Dividend

No data over the past 3 years
$467.17 M$582.13 M
$467.17 M$33.61 M

Analysts recommendations

Institutional Ownership

SRPT Latest News

Sarepta Therapeutics: BLA Filing Of SRP-9003 For LGMD Is The Next Step
seekingalpha.com08 November 2024 Sentiment: POSITIVE

Sarepta Therapeutics, Inc. reported Q3 2024 net product revenues of $429.8 million, a 39% year-over-year increase, driven by strong sales of ELEVIDYS and other DMD treatments. The company is advancing SRP-9003 gene therapy for LGMD, with phase 3 study results expected in early 2025 and a potential BLA filing by mid-2025. Despite strong revenues, Sarepta may need to raise additional funds within the next 12 months to support ongoing operations and development programs from its pipeline.

Sarepta Therapeutics, Inc. (SRPT) Q3 2024 Earnings Call Transcript
seekingalpha.com07 November 2024 Sentiment: POSITIVE

Sarepta Therapeutics, Inc. (NASDAQ:SRPT ) Q3 2024 Earnings Conference Call November 6, 2024 4:30 PM ET Company Participants Mary Jenkins - Associate Director, Investor Relations and Corporate Communications Douglas Ingram - President and Chief Executive Officer Dallan Murray - Executive Vice President and Chief Customer Officer Louise Rodino-Klapac - Executive Vice President, Chief Scientific Officer and Head of Research & Development Ian Estepan - Executive Vice President and Chief Financial Officer Conference Call Participants Tazeen Ahmad - Bank of America Merrill Lynch Gena Wang - Barclays Andrew Tsai - Jefferies Anupam Rama - JPMorgan Danielle Brill - Raymond James Eliana Merle - UBS Gil Blum - Needham & Company Ritu Baral - TD Cowen Joseph Schwartz - Leerink Partners Kostas Biliouris - BMO Capital Markets Brian Skorney - Baird Kristen Kluska - Cantor Fitzgerald Biren Amin - Piper Sandler Gavin Clark-Gartner - Evercore ISI Leo Watson - Mizuho Sami Corwin - William Blair Operator Good day and welcome to the Sarepta Therapeutics Third Quarter 2024 Financial Results Conference Call. After the speakers' presentation, there will be a question-and-answer session.

Sarepta Therapeutics (SRPT) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates
zacks.com06 November 2024 Sentiment: POSITIVE

While the top- and bottom-line numbers for Sarepta Therapeutics (SRPT) give a sense of how the business performed in the quarter ended September 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Sarepta Therapeutics Muscles Up In DMD Race
seekingalpha.com18 September 2024 Sentiment: POSITIVE

Sarepta's Elevidys received expanded FDA approval to treat both ambulatory and non-ambulatory DMD patients aged four and above. Although Elevidys missed its primary endpoint, it demonstrated success on secondary measures like motor function improvement and time-to-rise. SRPT expects substantial revenue growth, projecting net product revenues of $2.9-3.1 billion by 2025.

These 2 Biotech Stocks Are Set to Soar
fool.com13 September 2024 Sentiment: POSITIVE

Viking Therapeutics is inching closer to launching a weight loss product with multibillion-dollar potential. Sarepta Therapeutics continues to develop medicines for rare diseases whose sufferers have few options.

Why Is Sarepta Therapeutics (SRPT) Down 1.9% Since Last Earnings Report?
zacks.com06 September 2024 Sentiment: NEUTRAL

Sarepta Therapeutics (SRPT) reported earnings 30 days ago. What's next for the stock?

Bull Signal Flashing for Sarepta Therapeutics Stock
schaeffersresearch.com19 August 2024 Sentiment: POSITIVE

After touching a nearly four-year high of $173.25 on June 21, shares of biotech firm  Sarepta Therapeutics Inc (NASDAQ:SRPT) steadily worked lower on the charts, touching a more than two-month low of $123.50 on Aug. 9.

Biotech Stock Flashing Bull Signal
forbes.com14 August 2024 Sentiment: POSITIVE

Sarepta Therapeutics (SRPT) staged quite a slide after its June 21 three-year high of $173.25, closing six of the last seven weeks lower. The shares are in positive territory so far this week, however, as the stock extends a bounce off the $125 level.

2 Biotech Stocks to Buy Hand Over Fist in August
fool.com12 August 2024 Sentiment: POSITIVE

Vertex's newest approval and late-stage pipeline should yield stronger financial results. Smaller biotech Sarepta Therapeutics continues to innovate in its core therapeutic area.

Sarepta (SRPT) Q2 Earnings Top Estimates, Sales Lag, View Weak
zacks.com08 August 2024 Sentiment: NEUTRAL

Sarepta (SRPT) reports mixed results in the second quarter. It issues revenue guidance for 2025, which is below expectations.

What type of business is Sarepta Therapeutics?

Sarepta Therapeutics, Inc. is a biopharmaceutical corporation based in Cambridge, Massachusetts, specializing in medical research and the development of RNA-targeted therapeutic drugs for the treatment of rare diseases. It was founded in 1980. The company conducts clinical research and develops therapeutic drugs for a wide range of diseases. The company's product portfolio includes two approved commercial drugs: EXONDYS 51 - the first approved treatment targeting the underlying cause of Duchenne Muscular Dystrophy. VYONDYS 53 - a drug designed to treat Duchenne Muscular Dystrophy in patients with a mutation in the dystrophin gene (DMD).

What sector is Sarepta Therapeutics in?

Sarepta Therapeutics is in the Healthcare sector

What industry is Sarepta Therapeutics in?

Sarepta Therapeutics is in the Biotechnology industry

What country is Sarepta Therapeutics from?

Sarepta Therapeutics is headquartered in United States

When did Sarepta Therapeutics go public?

Sarepta Therapeutics initial public offering (IPO) was on 04 June 1997

What is Sarepta Therapeutics website?

https://www.sarepta.com

Is Sarepta Therapeutics in the S&P 500?

No, Sarepta Therapeutics is not included in the S&P 500 index

Is Sarepta Therapeutics in the NASDAQ 100?

No, Sarepta Therapeutics is not included in the NASDAQ 100 index

Is Sarepta Therapeutics in the Dow Jones?

No, Sarepta Therapeutics is not included in the Dow Jones index

When was Sarepta Therapeutics the previous earnings report?

No data

When does Sarepta Therapeutics earnings report?

The next expected earnings date for Sarepta Therapeutics is 28 February 2025